Abstract
Objectives: To investigate the choices hypoglycemic drugs for patients with newly diagnosed type 2 diabetes at theNational Hospital of Endocrinology. Subjects and methods: The study included 204 patients aged 16 to 81 with newly diagnosed with type 2 diabetes and were prescribed with hypoglycemic drugs. Results: Metformin was prescribed in 85% of patients as oral monotherapy. The most common oral drug combinations were metformin with DPP4 inhibitors or SGLT2 inhibitors, accounting for 41.9% and 22.6%, respectively. Among the patients using insulin, insulin monotherapy and its combination with metformin were prescribed in most patients, accounting for 62.5% và 21.3%, respectively. In patients with HbA1c < 7%, 88,5% received oral monotherapy; the ones with HbA1c 7 - <8.5%: 64% and 32% received oral drug combination and monotherapy, respectively; the ones with HbA1c 8.5 - <10%: 67,9% received oral drug combination and 32% used insulin; with HbA1c ≥ 10%: 88,4% and 10,3% used insulin and oral drug combinations, respectively. Conclusions: In patients with newly diagnosed type 2 diabetes, metformin was used by most patients as monotherapy or in combination with other drugs. New oral hypoglycemic drugs were prescribed for a significant proportion of the patients. Most hypoglycemic drug choices followed present recommendations. However, there was some overuse of hypoglycemic drugs in patients with slightly to moderately elevated HbA1c, and in contrary some underuse in patients with very high HbA1c.